Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials: Integrated approaches can help enhance recruitment plans.

The article discusses integrated approach for enhancing enrollment in biomarker-driven oncology and rare disease trial. It discusses most of the clinical trials are done in the oncology department compared to other disease, it presents Food and Drug Administration (FDA)-approved biomarker-driven therapies and discusses that biomarkers enable researchers to understand science behind any disease and provides personalized medicines approved by Food and Drug Administration.